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Abstract
Although electroconvulsive therapy (ECT) is among the most effective treatment options for pharmacoresistant major
depressive disorder (MDD), some patients still remain refractory to standard ECT practise. Thus, there is a need for
markers reliably predicting ECT non/response. In our study, we have taken a novel translational approach for
discovering potential biomarkers for the prediction of ECT response. Our hypothesis was that the promoter
methylation of p11, a multifunctional protein involved in both depressive-like states and antidepressant treatment
responses, is differently regulated in ECT responders vs. nonresponders and thus be a putative biomarker of ECT
response. The chronic mild stress model of MDD was adapted with the aim to obtain rats that are resistant to
conventional antidepressant drugs (citalopram). Subsequently, electroconvulsive stimulation (ECS) was used to select
responders and nonresponders, and compare p11 expression and promoter methylation. In the rat experiments we
found that the gene promoter methylation and expression of p11 signiﬁcantly correlate with the antidepressant effect
of ECS. Next, we investigated the predictive properties of p11 promoter methylation in two clinical cohorts of patients
with pharmacoresistant MDD. In a proof-of-concept clinical trial in 11 patients with refractory MDD, higher p11
promoter methylation was found in responders to ECT. This ﬁnding was replicated in an independent sample of 65
patients with pharmacoresistant MDD. This translational study successfully validated the ﬁrst biomarker reliably
predicting the responsiveness to ECT. Prescreening of this biomarker could help to identify patients eligible for ﬁrst-
line ECT treatment and also help to develop novel antidepressant treatment procedures for depressed patients
resistant to all currently approved antidepressant treatments.
Introduction
Depression is a major cause of disability worldwide;
however, despite several decades of intense research, our
understanding of the pathophysiology of major depressive
disorder (MDD) remains limited1,2. Treatment with
antidepressant drugs is ineffective in up to two-third of
depressed patients and, when effective, delayed in onset and
afﬂicted with side effects3,4. Thus, there is a major unmet
medical need for more effective therapies. Electroconvulsive
therapy (ECT) remains the most effective treatment option
for drug-refractory depressed patients, but its mechanisms
still remain elusive5–7. Furthermore, approximately one
third of pharmacoresistant depressive patients are resistant
to ECT as well8,9. Biomarkers reliably predicting the
response to ECT would not only signiﬁcantly reduce costs
and identify patients eligible for ﬁrst-line ECT treatment
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but also help to develop novel ECT and other treatment
procedures for a subgroup of depressed patients resistant to
currently approved antidepressant treatments.
The overall aim of the present study was to identify
potential biomarkers for ECT response by developing a
valid rat model of pharmacoresistant depression and then
translate the experimental ﬁndings to depressive patients in
a proof-of-concept (POC) clinical study. Validated animal
models of depression are based on the observation that
chronic stress is a central causal factor for the development
of MDD10. The chronic mild stress (CMS) model was
developed to mimic anhedonia—one of the core symptoms
of MDD11. We adapted this model with the aim to obtain
rats that are resistant to conventional antidepressant drugs
(citalopram). Afterwards, such animals were treated with
two different types of ECT as recently described12. Based on
a recent study with this animal model of depression13,
showing a rat breeder-dependent effect of CMS on p11
methylation, our hypothesis was that the expression and
promoter methylation of p11, a member of the S100 EF-
hand family14, might be differently regulated in ECT
responders compared with nonresponders and thus be a
putative biomarker of ECT response. This hypothesis is
supported by several lines of evidence. In our recent rat
study, vulnerability and resilience of different Wistar rat
substrains to CMS were reﬂected in epigenetic regulation
and expression of p1113. Moreover, p11 is decreased in
prefrontal cortex (PFC), hippocampus, and nucleus
accumbens of depressed patients and in animal models of
depression, whereas antidepressants and ECT increase p11
in the rodent brain15. P11 ampliﬁes serotonin receptor-
mediated signaling and regulates gene transcription16. The
precise mechanisms underlying the antidepressant therapy-
associated increase in p11 levels remains obscure, but they
appear to involve an upregulation of brain-derived neuro-
trophic factor (BDNF) signaling15. Indeed, BDNF and its
epigenetic regulation have been associated with both the
pathophysiology of depression and the mode of action of
antidepressant treatments17–21. In line with this concept, we
recently reported that pharmacoresistant depressive
patients remitting under ECT had signiﬁcantly lower mean
promoter methylation rates of the BDNF gene compared
with nonremitters22. Therefore, we also included BDNF
promoter methylation measurements in the present animal
experiments.
Materials and methods
See Supplementary Material for additional details.
Preclinical experiments
The design of the preclinical experiments is illustrated
in Fig. 1. For the preclinical experiments, 46 male Wistar
outbred rats (Charles River, Sulzfeld, Germany) under-
went the CMS protocol, 10 age-matched male Wistar rats
served as unstressed controls. We have previously
shown13 that Wistar outbred rats from this vendor exhibit
increased anxiety-related behavior and increased response
to CMS compared with such rats from other vendors so
that we expected that CMS-induced behavioral alterations
induced in this Wistar substrain (Crl : WI(Han)) might be
particularly severe and difﬁcult to treat by anti-
depressants. Depression-like symptoms were measured by
a battery of behavioral tests, as one behavioral test alone
might not capture a more complete picture of the effects
of CMS, citalopram, and the ECT treatment. This battery
included the sucrose consumption test (SCT), the forced
swim test, novelty-induced hypophagia, the open-ﬁeld
test, and the social interaction test. As in the experiments
of Christensen et al.23, sucrose consumption rather than
sucrose preference was measured, because the SCT has
been established by Wiborg and colleagues23 as a well-
suited measure to select for responders and non-
responders to antidepressive treatment. All rats were
randomly assigned to treatment groups. Electroconvulsive
stimulation (ECS) was applied as previously described12.
Classiﬁcation of treatment response was deﬁned by the
within-subject change in sucrose consumption according
to Christensen et al.23. Rats were anesthetized and
decapitated 24 h after the last (sham)-ECS, citalopram, or
vehicle treatment for analysis of p11 and BDNF in the
PFC. See Supplementary Material for details of the animal
experiments, biochemical analyses, and statistical evalua-
tion of data.
Clinical experiments
A prospective POC clinical study was performed in 11
in-patients with a pharmacoresistant depression receiving
ECT, recruited at the University Hospital of Erlangen
(Ethics number: 3252/2006). Response was deﬁned by a ≥
50% reduction of the Montgomery Asberg Depression
Scale. Fasting blood samples were taken directly before
(8–10 a.m.) ECT sessions 1, 4, 7, and 10. For the inde-
pendent replication sample, 67 in-patients with a phar-
macoresistant depression receiving ECT were acquired at
the Department of Psychiatry of the Charité Berlin, to
assure the blinded performance of the molecular analyses
(Ethics number: EK-224-05c). Depression severity was
assessed before and weekly (for 6 weeks) during ECT
treatment. A ≥ 50% reduction of the Hamilton Depression
Rating Scale (HAMD) within the treatment period was
interpreted as response to therapy: Fasting blood samples
(n = 65) were taken once before the initation of the ECT
treatment series. There were no outliers excluded from
the analyses. Antidepressant and antipsychotic medica-
tion (as well as total leucocyte counts measured in the
replication sample) did not differ between responders and
non-responders to therapy. In both clinical studies,
informed consent was obtained after the nature and
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possible consequences of the studies were explained. See
Supplementary Material and Supplemental Tables S1 and
S2 for details of the clinical trials, biochemical analyses,
and statistical evaluation of data.
Results
CMS-induced alterations in sucrose consumption in rats
The 3-week sucrose consumption course of unstressed
control rats demonstrated that none of the control ani-
mals showed anhedonic-like behavior (Fig. 2a and Table
1). Stressed rats were classiﬁed after 3 weeks of CMS as
anhedonic-like or hedonic-like, based on changes in
intake of sucrose solution. According to Christensen
et al.23, anhedonic-like rats are supposed to show a > 25%
within-subject decrease in sucrose consumption.
Hedonic-like rats are supposed to show a < 10% within-
subject decrease in sucrose consumption. Animals not
responding to either criterion are considered as unclas-
siﬁable. In experiment I, CMS-induced anhedonic-like
behavior was present in 66.7% (10/15) of the animals,
whereas hedonic-like behavior was detected in 13.3% (2/
15) of the rats (Fig. 2b and Table 1). Equally, about 60%
(17/29) of CMS-exposed rats from experiment II showed
anhedonic-like behavior and 21% (6/29) of the rats were
classiﬁed as hedonic-like after CMS (Fig. 2c and Table 1).
The average weekly body weight gain during three weeks
of CMS was 7.6 g (range 3.3–10.6 g), so that weight gain of
all CMS-exposed rats was below the average weight gain
of naïve male Wistar rats of 15 g per week.
Effects of citalopram on sucrose consumption in the CMS
model in rats (experiment I)
Chronic citalopram treatment did not increase the
intake of sucrose solution in any of the preassigned
anhedonic-like rats (Table 1) so that they were classiﬁed
as sub-categorical nonresponders. Examples of vehicle
and citalopram-treated anhedonic-like rats are shown in
Fig. 2d, e; data from all individual rats are shown in Figs
S1 and S2. No behavioral adverse effects were observed
during treatment with citalopram, but rats lost body
weight compared to vehicle controls. One hedonic-like
and one unclassiﬁable animal became anhedonic-like
during citalopram (Fig. S2).
Effects of ECS on sucrose consumption in the CMS model
in rats (experiment II)
As shown in Fig. 1b, ECS was delivered once daily for
5 days. Afterwards, behavioral investigations were con-
ducted before ECS was applied for further 2 days. CMS
was continued during the stimulation period. After ﬁve
ECS treatments, rats were classiﬁed according to their
changes in sucrose intake (Table 1). Examples of sham
and ECS-treated anhedonic-like rats are shown in Fig.
2f–i; data from all individual rats are shown in Figs S3–S5.
Sham ECS exerted no signiﬁcant effects in anhedonic-like
rats (Fig. 2f). After cortical ECS, 67% (four of six) of
anhedonic-like rats showed positive response (Fig. 2g and
Table 1), whereas two of these rats did not respond (Fig.
2h). In contrast, about 80% (5/6) of anhedonic-like ani-
mals, which received auricular ECS, were characterized as
nonresponders. Overall, cortical ECS was the only treat-
ment that exerted a signiﬁcant antidepressive effect in this
rat model of drug-resistant chronic depression (Table 1).
As previously described in Theilmann et al.12, cortical
and auricular ECS induced mainly generalized convulsive
seizures of at least 15 s duration (mean seizure duration (
± SEM) cortical ECS: 25.5 (± 1.35) s, mean seizure
duration (± SEM) auricular ECS: 21.9 s (± 0.97)), as
Fig. 1 Schematic protocol of the two preclinical experiments. In experiment I a, the effects of citalopram on CMS-induced behavioral alterations were
determined, whereas the effects of ECS were evaluated in experiment II b. Abbreviations: CMS, chronic mild stress; ECS, electroconvulsive stimulation;
FST, forced swim test; NIH, novelty-induced hypophagia; OFT, open ﬁeld test; SCT, sucrose consumption test; SIT, social interaction test
Neyazi et al. Translational Psychiatry  (2018) 8:25 Page 3 of 13
evident in the cortical electroencephalogram (EEG). Rats
with cortical ECS showed predominantly generalized
clonic seizures, whereas auricular ECS induced mainly
tonic extensions of fore- and hindlimbs. We could also
replicate our previous ﬁnding12 that signiﬁcantly (P=
0.025) more rats with auricular ECS (7/10 animals)
emitted calls of fear and distress (22 kHz) before and after
stimulation than cortically stimulated rats (2/10 animals).
Effects of ECS on other depression-like symptoms in the
CMS model in rats
In addition to the positive effect on sucrose consump-
tion in the CMS model, cortical ECS signiﬁcantly
increased body weight, whereas it was decreased by
auricular ECS (Fig. 3a). Furthermore, cortical, but not
auricular ECS, decreased the duration of immobility in the
forced swim test (Fig. 3b), a classical test assessing
antidepressant-like behavioral responses. Auricular ECS
exerted negative effects on novelty-induced hypophagia
(Fig. 3c, d), adding to the overall negative response to this
type of ECS. No signiﬁcant intergroup differences were
seen in the open ﬁeld (time in center; P= 0.317) and
social interaction tests (distance between animals, P=
0.981; time in body contact, P= 0.613) (not illustrated).
When sub-categorical positive responses were calculated
from all behavioral tests, cortical ECS was the only
Fig. 2 Individual responses to chronic mild stress (CMS) and antidepressive treatments in the sucrose consumption test in rats. a Illustrates that
sucrose consumption survey over 3 weeks in unstressed control rats results in 8 out of 10 rats with hedonic-like behavior, whereas 2 rats were
unclassiﬁable. b Data from experiment I, showing that 3 weeks of CMS induced anhedonic-like behavior in 10 out of 15 animals. Thus, the number of
anhedonic-like rats was increased after CMS compared with unstressed controls (P = 0.0024). Hedonic-like behavior was present in 2 out of 15
animals. c Data of experiment II, showing that 3 weeks of CMS-induced anhedonic-like behavior in 17 out of 29 rats. Thus, the number of anhedonic-
like rats was increased after CMS compared with unstressed controls (P = 0.0015). Hedonic-like behavior was present in 6 out of 29 rats. Small dashed
lines represent threshold for selection of hedonic- and anhedonic-like rats (anhedonic-like rats > 25% within-subject decrease in sucrose
consumption, hedonic-like rats < 10% within-subject decrease in sucrose consumption). d–i Representative data from individual rats following
different types of antidepressive treatment. d A vehicle-treated rat from experiment I; e a citalopram-treated non-responder from experiment I; f a rat
from experiment II after ﬁve sham ECS sessions; g a responder from experiment II after ﬁve cortical ECS sessions; h a nonresponder from experiment II
after ﬁve cortical ECS sessions; and i a nonresponder from experiment II after ﬁve auricular ECS sessions. Responses of all treated rats are shown in
Table 1. Wide dashed lines represent the threshold for positive response and solid lines represent threshold for negative treatment response. See Figs.
S1–S5 for data of all individual rats
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effective antidepressant treatment in the CMS model (Fig.
3e), whereas auricular ECS induced signiﬁcantly more
negative responses than sham treatment (Fig. 3f), and
citalopram was not effective in any of the tests (Fig. 3e, f).
It is interesting to note that sham-treated animals, as a
group, appeared anhedonic in the SCT after CMS (Fig. 2f;
Table 1) but less anxious/depression-like in the novelty-
induced hypophagia (Fig. 3c). Given that depression is a
heterogeneous and complex disorder, it is unlikely to be
that all CMS-exposed animals with hedonic disturbance
show necessarily depressive-like behaviors in other
depression-related symptoms and vice versa. Although
the SCT and the novelty-induced hypophagia test are
both based on the consumption of palatable nutrients,
they still differ in other behavioral components, which
might have been the crucial components for the rats to
perform differently in one test compared with the other.
Correlation between antidepressive response of ECS in the
CMS model and alterations in p11 or BDNF
In order to study whether alterations in p11 or BDNF
were associated with the antidepressive effect of ECS in
the CMS rat model, we compared three groups of rats:
anhedonic-like sham controls, rats with ECS-positive
response in the SCT, and rats with no or negative
response to ECS in the SCT (Fig. 4). As shown in Fig. 4a,
the percent change in sucrose intake following ECS
treatment in responders was signiﬁcantly different from
sham and non/negative responders. P11 promoter
methylation was signiﬁcantly increased in the PFC of ECS
responders (Fig. 4b). Furthermore, p11 mRNA expression
was signiﬁcantly higher in PFC of responders (Fig. 4c). In
contrast to p11, BDNF did not discriminate between ECS
responders and nonresponders (Fig. 4d, e). As shown in
Fig. 4d, BDNF promoter methylation did not differ among
groups, while both ECS groups exhibited signiﬁcantly
higher BDNF protein expression than sham controls (Fig.
4e).
POC study in patients with pharmacoresistant MDD
Based on the preclinical data, we examined whether
patients (N= 11) differing in their response to ECT also
differ in peripheral p11 promoter methylation. Patients’
baseline characteristics are shown in Table S1. At the end
of the ECT series four patients had responded to ECT.
Mixed linear modelling showed no change in p11 pro-
moter methylation over time but revealed differences
between responders and nonresponders: p11 promoter
methylation was signiﬁcantly higher in responders than in
nonresponders before each ECT (Fig. 5a, b; for methyla-
tion at different CpG sites see Supplemental Figure S10A).
Prediction of response in an independent clinical
replication sample
Based on the POC study, p11 promoter methylation was
studied in an independent replication sample of 65
pharmacoresistant patients receiving ECT. Baseline
characteristics of the replication sample are shown in
Table S2. We could replicate our ﬁnding of higher base-
line p11 promoter methylation in responders to ECT
Table 1 Results from sucrose consumption test of the two experiments illustrated in Figs 1 and 2
Response in sucrose
consumption test
Experiment I Experiment II
Controls
without CMS
(n = 10) Exp.
#1a
CMS CMS
Citalopram ECS
Before
treatment (n
= 15) Exp. #1b
After treatment Before
treatment (n
= 29) Exp. #2a
After treatment
Vehicle (n
= 8) Exp.
#1c
Citalopram (n
= 7) Exp. #1d
Sham (n
= 9) Exp.
#2b
Cortical
ECS (n =
10) Exp.
#2c
Auricular ECS
(n = 10) Exp.
#2d
Hedonic 8 2 1 0 6 3 6 2
Anhedonic 0 10 7 7 17 6 2 8
Unclassiﬁable 2 3 0 0 6 0 2 0
Signiﬁcance of
differences in
proportion of hedonic
rats (Fisher’s exact test)
P = 0.0024 vs.
#1a
NS vs. #1b NS vs. #1b P = 0.0015 vs.
#1a
NS vs.
#2a
P = 0.0427
vs. #2a
NS vs. #2a
As described in Methods, the animals were randomly divided into the treatment groups and it was ensured that the number of anhedonic-like, hedonic-like, and
unclassiﬁable rats were almost the same in all treatment groups
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compared with nonresponders (Fig. 5c; for methylation at
different CpG sites see Supplemental Figure 10B).
Next, we performed receiver operating characteristic
(ROC) analyses to validate the potential usefulness of p11
promoter methylation to predict response to ECT. Our
ROC curves revealed that p11 promoter methylation
levels above the threshold of 72.15% were robust to dis-
criminate responders from nonresponders with AUC
values of 0.711 (95% conﬁdence interval (CI): 0.575–0.846;
Fisher’s exact test P= 0.006, Fig. 5d). The sensitivity and
speciﬁcity to identify responders was 70% and 73%,
respectively (Fig. 5e). The odds ratio for patients with
Fig. 3 Effect of ECS in behavioral tests other than sucrose consumption and overall responses to antidepressive treatments in rats. a–d Grouped
behavioral assessment after sham ECS, cortical ECS, and auricular ECS arranged by treatment groups. Data are shown as means ± SEM of 9 (sham), 10
(cortical ECS, and 10 (auricular ECS) rats. a Weight changes (g) (**P < 0.01, ***P < 0.001, comparing sham with auricular and cortical ECS) before and
after ECS sessions. b Percentage change of immobility time in the forced swim test from test to re-test session. Test session was performed 2 days
before ECS started. Re-test trial was performed 1 day after the ﬁfth ECS (**P < 0.01, comparing sham with auricular and cortical ECS). c Change in
latency to eat (s) (**P < 0.01, comparing sham with auricular and cortical ECS) from novelty-induced hypophagia test to re-test session. d Food intake
(g) (**P < 0.01, comparing sham with auricular and cortical ECS) from novelty-induced hypophagia test to re-test session. Test session in b and c was
performed 1 day before ECS. Re-test trial was performed 2 days after the ﬁfth ECS. e and f Summary of treatment effects caused by vehicle vs.
citalopram treatment and sham, cortical, and auricular ECS, including data from all tests shown in Table S3. e Total number of direct treatment
responses. Vehicle and citalopram groups did not differ in responses (P = 0.903). Cortical ECS induced signiﬁcantly more treatment responses
compared with sham ECS (**P < 0.01), whereas auricular ECS was ineffective. f Total number of direct negative treatment responses. There were no
signiﬁcant differences between rats with vehicle and citalopram (P = 0.952). Auricular ECS was associated with signiﬁcantly more negative responses
than sham or cortical ECS (*P = 0.05)
Neyazi et al. Translational Psychiatry  (2018) 8:25 Page 6 of 13
Fig. 4 (See legend on next page.)
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serum p11 promoter methylation cutoff threshold values
of > 72.15% to respond to ECT was 6.417 (95% CI:
1.759–23.413). P11 hypermethylation predicted ECT
response with a probability of 89%. Furthermore, there
was a signiﬁcant difference in the percentage of HAMD
score reduction between p11-positive and p11-negative
patients at week 5 (Bonferroni corrected post-hoc tests
following two-way analysis of variance P< 0.05) and 6 (P
< 0.01) (Fig. 6).
To further conﬁrm the reproducibility of p11 promoter
methylation as a marker for response to ECT we applied
the derived cutoff from Youden’s Index to our POC study
and could distinguish responders from nonresponders to
ECT (Fisher’s exact test (one-sided) P= 0.045, Fig. 5f). All
responders had p11 methylation levels above the thresh-
old of 72.15%.
Discussion
The CMS model of depression24 is a highly validated
method to reﬂect symptoms (endophenotypes) of human
MDD in rats and to analyze antidepressant therapy
effects. As a core symptom of MDD, CMS causes changes
in hedonic-like behavior, which are mirrored by decreased
intake or preference of sweetened solution. Some studies
demonstrated CMS-induced segregation of rats in sub-
groups that either show anhedonic-like behavior or
revealed resilience to CMS23,25,26, which was also
observed in the present study. Moreover, CMS induces
various other depression-like symptoms, including
increased behavioral despair (e.g., immobility in the forced
swim test) and learned helplessness, decreases in self-care,
loss of body weight, and sleep changes27. Almost every
study that has examined the effects of chronic treatment
with antidepressant drugs, including citalopram or esci-
talopram, has reported that such drugs were effective in
reversing or preventing these ‘depressive’ behavioural
changes in the CMS model27, although some studies
reported that a subgroup of the treated rats was resistant
to antidepressant drugs23,26,28. By using a substrain (Crl:
WI(Han)) of male outbred Wistar rats that is particularly
stress-sensitive13, we established a CMS model in which
all examined rats were resistant to citalopram, thus
establishing a novel rat model of drug-resistant chronic
depression that can be used to explore the efﬁcacy of
alternative treatments such as ECS and to discover bio-
markers predicting ECS response. Our recent study in
outbred Wistar substrains from different vendors had
shown that the differences to CMS in these substrains are
reﬂected in epigenetic regulation and expression of p1113,
so that p11 seemed to be a good candidate for the aims of
the present ECS study.
Treatment-resistant depression or treatment-refractory
depression is a term used in clinical psychiatry to describe
cases of MDD that do not respond adequately to appro-
priate courses of at least two antidepressants3,4. Thus, the
fact that we included only one drug, citalopram, in the
present rat experiments is a limitation of the model and
we plan to characterize the drug resistance of the model
in more detail in the future. Furthermore, an independent
replication of the preclinical ﬁndings with this complex
chronic model would be helpful, as this experiment has
been done only once. Studies on the effect of ECS (the
analog to ECT in animals) in validated animal models of
depression are sparse; however, repeated auricular ECS
treatments have been shown to reverse stress-induced
anhedonia in the CMS rat model29,30. In the present
study, cortically applied ECS was clearly more effective
than citalopram to reduce anhedonia, which is in line with
clinical experience. However, as already noted by Hen-
ningsen et al.30, not all rats responded to ECS so that
responders and nonresponders could be selected. When
comparing cortical ECS with auricular ECS, as used in the
studies of Moreau et al.29 and Henningsen et al.30 and
most other ECS studies in animals, cortical ECS was
clearly more effective to reduce depression-like symptoms
in the chronic CMS model, substantiating our recent
study with an acute depression model12. Furthermore,
auricular ECS was associated with adverse effects that
were signiﬁcantly less often or not at all observed with
cortical ECS, which we therefore consider a more valid
procedure to mimic ECT. As cortical ECS has higher
construct validity than auricular ECS (because, as in
patients, cortical ECS stimulates the cerebral cortex and
not the brain stem as auricular ECS), we assume that
Fig. 4 Association between ECS responses in the sucrose consumption test (SCT) in rats and p11 and BDNF expression and promoter methylation in
the prefrontal cortex (PFC). As shown in a, three groups of rats were compared: anhedonic-like sham controls, rats with ECS-positive response in the
SCT, and rats with no or negative response to ECS in the SCT. Data are shown as means ± SEM of 6 (anhedonic-like sham), 5 (positive ECS response),
and 10 (no or negative ECS response) rats. In a, the percent change in sucrose intake following ECS treatment in responders was signiﬁcantly different
from sham and non/negative responders (**P < 0.01, comparing anhedonic-like sham animals with positive responders and non/negative
responders). b Signiﬁcant difference of the three groups regarding p11 methylation in PFC (* P = 0.017). c Similarly, such an effect was seen for p11
mRNA expression in PFC (***P < 0.001 comparing positive responders with anhedonic-like sham animals and P = 0.004 comparing positive
responders and non/negative responders). d BDNF methylation was not different between groups (P = 0.284, comparing anhedonic-like sham
animals with positive responders and non/negative responders), whereas ECS responders and non/negative responders e signiﬁcantly differed from
anhedonic-like sham rats in BDNF expression in PFC (*P < 0.05)
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Fig. 5 Association between clinical response to ECT and p11 promoter methylation. Data are shown as means ± SEM; signiﬁcant differences between
groups are indicated by asterisks (*P < 0.05; **P < 0.01; ***P < 0.0001). As shown in a and b, p11 promoter methylation was higher in responders (n =
4) compared with nonresponders (n = 6) directly before ECT sessions 1, 4, 7, and 10 (response: P < 0.0001; ECT-number: P = 0.094, derived from mixed
linear modelling including the factors age and gender). c Higher baseline p11 promoter methylation of responders (n = 50) compared with
nonresponders (n = 15) to ECT in the independent clinical replication sample (P = 0.014, derived from mixed linear modelling including the factors
age and gender). d ROC curve analysis to evaluate the efﬁciency of p11 promoter methylation levels in differentiating responders fron nonresponders
in the independent clinical replication sample with area under the curve values (AUC) of 0.711 (95% CI: 0.575–0.846; P = 0.006). Values of above the
threshold of 72.15% (derived from Youden’s Index) were robust to discriminate responders from nonresponders with a sensitivity of 70% and speciﬁty
of 73% as shown in e. P11 hypermethylation predicted ECT response with a probability of 89%. f The derived cutoff from Youden’s Index was
sufﬁcient to distinguish responders (all above the threshold of 72.15%) from nonresponders in the POC study (P = 0.045)
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cortical ECS as an antidepressive treatment in the CMS
model has a higher translational value than auricular ECS.
Furthermore, the signiﬁcant adverse effects (fear calls,
weight loss, and transient motor paralysis) associated with
auricular ECS12 raise ethical concerns against this
method, whereas tolerability of cortical ECS in rats is
much better.
After establishing cortical ECS as an effective treatment
to reduce depression-like symptoms in the CMS model,
the major aim of our study was to identify potential bio-
markers for ECT response. Considerable experimental
evidence implicates p11 in the mechanism of action of
antidepressant drugs and ECS, in part due to its interac-
tion with BDNF and speciﬁc serotonin (5-HT) and glu-
tamate receptors15,31, so that our hypothesis was that ECT
responders differ from nonresponders in respect to p11
expression or epigenetic regulation. Indeed, a higher p11
mRNA expression was found in PFC of ECS responders,
which was paralleled by a signiﬁcantly increased BDNF
expression, which, however, was also signiﬁcantly
increased in ECS nonresponders. Furthermore, p11 pro-
moter methylation was increased in PFC of ECS respon-
ders, whereas BDNF promoter methylation was not
altered. These ﬁndings prompted us to perform a clinical
POC study focusing on peripheral p11 promoter methy-
lation in pharmacoresistant MDD patients that respond
or do not respond to ECT. In this prospective (long-
itudinal) study, we found higher p11 promoter methyla-
tion levels in patients who responded to ECT. The
observed differences were present at baseline and during
the ECT course, although there were no acute changes in
peripheral p11 promoter methylation after treatment.
Most importantly, we were able to replicate this ﬁnding in
an independent cohort of 65 depressed patients receiving
ECT.
To our knowledge, this is the ﬁrst study that, based on
both preclinical and clinical evidence, indicates that p11
methylation may be a suitable biomarker of ECT response
in MDD. p11 levels are regulated by BDNF32 and several
previous studies have investigated whether serum BDNF
could be a biomarker for therapy response to ECT, but
inconsistent results were obtained24,33. Thus, as indicated
by a recent systemic review and meta-analysis, ECT can
enhance serum BDNF levels, but this effect does not
necessarily correlate with its clinical response in depres-
sion33,34. The complex regulation of BDNF expression
underlies epigenetic mechanisms, such as histone mod-
iﬁcation and DNA methylation35. With respect to ECT
response, we recently found that BDNF promoter
methylation rates, especially concerning the exon I pro-
moter, may be more suited than BDNF serum levels to
predict an antidepressant effect of ECT in pharmacore-
sistant MDD patients22.
Behavioral studies demonstrated that p11 knockout
mice are insensitive to the antidepressant actions of
BDNF32. Only two studies, to our knowledge, have
investigated p11 as a biomarker for responsiveness to
antidepressant treatments36,37. In one study, no differ-
ences between responders and nonresponders to therapy
with escitalopram or nortriptyline were reported for leu-
kocyte mRNA levels of p1136, whereas the other study
found that MDD patients that responded to citalopram
had lower p11 levels in natural killer cells and monocytes
than nonresponders37. As noted by the authors, it appears
paradoxical that a decrease of p11 in white blood cells
should be associated with antidepressant response, as
animal studies have shown that antidepressants increase
p11 in the brain15. Melas et al.38 reported that this
increase of p11 after administration of escitalopram was
accompanied by a hypomethylation within the p11 pro-
moter region in the PFC of the Flinders Sensitive Line
genetic rodent model of depression.
In contrast to the study by Melas et al.38, we observed
higher p11 expression accompanied by higher p11 pro-
moter methylation in the PFC of responders to ECS. In
our clinical sample we observed higher p11 promoter
methylation in blood samples of responders to ECT.
The positive correlation between p11 promoter
methylation and p11 expression is in line with recent data
from our laboratory showing a positive correlation of p11
methylation and transcriptional activity in the hippo-
campus and PFC of rats13.Moreover, there is growing
evidence that the function of CpG methylation is not
necessarily gene silencing, for example due to hyper-
methylation of repressive elements39,40. Probably, the
observed methylation differences in responders are not
Fig. 6 HAMD score reduction and baseline p11 methylation status.
Signiﬁcant differences between groups are indicated by asterisks (*P <
0.05; **P < 0.01; ***P < 0.0001). P11-positive patients at baseline
(methylation above Youden’s Index cutoff, n = 39) showed a
signiﬁcantly higher reduction in the HAMD score when compared
with p11-negative patients (n = 26) at week 5 and 6
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speciﬁc to p11 but to other genes with a similar regulation
pattern. The difference between our results and the ones
reported by Melas et al.38 could also be explained by the
difference in the measured p11 sequence, as our fragment
also covered the regulatory region of exon I near the p11
promoter. Furthermore, we already showed that different
substrains of rats respond differently to CMS, reﬂected by
different p11 methylation and expression13.
Nevertheless, two studies on the epigenetic regulation of
the p11 gene showed a lower expression in association
with a hypermethylation of the p11 promoter region, one
in primary human pituitary tumors and another in
medulloblastoma primary tumors and cell lines41,42. Thus,
ECS-induced hyperexpression could also have caused p11
hypermethylation as a regulating feedback loop.
Our study is restricted in its ability to understand the
pathophysiology behind the observed differences in p11
methylation. Nevertheless, one could speculate that p11
functionality at baseline is necessary for ECT to be fully
effective or that our ﬁndings point to a subgroup of
depressed patients, especially sensitive to ECT. Possibly,
higher p11 expression and/or methylation at baseline is
favorable for the ECT-induced neurogenesis via BDNF. In
this regard, it is interesting to note that p11 activates
tissue plasminogen activator, which is involved in the
cleavage of proBDNF to BDNF43. Furthermore, the
BDNF-induced neural plasticity has been proposed to be
dependent on p11 in a cell culture model44.
Alternatively, the higher p11 methylation in responders
could point to a subgroup of patients in whose p11
hypermethylation (and possibly low expression of p11)
indicate a trait of MDD sensitive to ECT.
Our study has several limitations. These include the fact
that we did not assess p11 or BDNF methylation or
mRNA in the peripheral circulation of rats. Furthermore,
due to technical reasons, we were not able to assess p11
mRNA or BDNF mRNA in the samples collected from
patients. Thus, we can only speculate about the expres-
sion of p11 in the clinical cohort and future studies are
needed to understand the regulatory mechanisms of p11
methylation to obtain a more mechanistic insight. In
addition, we cannot exclude differences in peripheral cell
composition of responders and nonresponders that could
have inﬂuenced our methylation results. Furthermore, we
performed no single-nucleotide polymorphism analysis in
the p11 gene, which could probably have inﬂuenced p11
methylation. Another limitation is our highly selective
patient cohort, which included only severely affected and
medicated patients. Thus, we were not able to control for
medication and future studies are needed to clarify the
speciﬁcity of response prediction of p11 methylation
regarding different treatment options.
In conclusion, we have taken a novel approach to
studying whether p11 or its epigenetic regulation is a
potential biomarker of response to ECS/ECT. First, we
modiﬁed a widely used rat model of chronic depression,
CMS, by using a rat substrain that is particularly stress-
sensitive, and, as shown here, resistant to the anti-
depressant citalopram. Next, ECS was shown to be more
effective than citalopram in this model, thus allowing to
select ECS responders and nonresponders. The response
to ECS was correlated with p11 mRNA expression and
methylation in PFC, which prompted a POC clinical pilot
trial in patients with refractory MDD, showing higher p11
promoter methylation in remitters to ECT. In an inde-
pendent replication sample acquired in a different uni-
versity hospital by independent researchers, we were able
to replicate these differences in baseline p11 methylation
and tested the predictive properties of p11. We found that
patients with a p11 methylation below a threshold with
highest sensitivity and speciﬁcity had a fourfold increased
risk for nonresponse to treatment, whereas in the same
sample elevated p11 methylation predicted response to
ECT with positive predictive value of around 90%. Using
the same thresholds in the POC sample, we found that all
responders had p11 hypermethylation above the thresh-
old, indicating that p11 promoter methylation is a suitable
biomarker for response to ECT.
Within the last years, increasing efforts have been made
to search for epigenetic biomarkers of response to phar-
macological antidepressant treatments. Regarding ECT,
there is only limited data on epigenetic effects of ECT in
general. Up to date, our previous study on BDNF
methylation22 is the only investigation on epigenetic
alterations of a candidate gene as a possible biomarker for
response to ECT. Furthermore, most of the studies on
ECS in rodent models do not distinguish between
response types and thus have only limited translational
value to identify possible biomarkers.
We show for the ﬁrst time that a translationally and
clinically valid biomarker—p11 methylation—can distin-
guish between responders and nonresponders of ECT
treatment before the ﬁrst treatment is initiated, which
allows for an individualization of treatment strategies in
pharmacoresistant depression. Patients likely to respond
to ECT should receive ECT treatment more easily and
probably more early in the course of the disorder. Patients
likely not responding to ECT should not receive ECT
treatment, which will lead to increased acceptance of this
still stigmatized treatment option. Further studies are
needed to elucidate additional markers increasing the
predictive power to distinguish between responders and
nonresponders to ECT, and to identify other treatment
options effective for ECT-resistant patients.
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